STAT

STAT is a family of cytoplasmic protein that regulates many aspects of growth, survival and differentiation in cells. The transcription factors of this family are activated by Janus kinase and dysregulation of this pathway is frequently observed in primary tumours and leads to increased angiogenesis, enhanced survival of tumours and immunosuppression. Gene knockout studies have provided evidence that STAT proteins are involved in the development and function of the immune system and play a role in maintaining immune tolerance and tumour surveillance. STAT proteins were originally described as latent cytoplasmic transcription factors that require phosphorylation for nuclear retention. The unphosphorylated STAT proteins shuttle between cytosol and the nucleus waiting for its activation signal. Once the activated transcription factor reaches the nucleus, it binds to consensus DNA-recognition motif called gamma-activated sites (GAS) in the promoter region of cytokine-inducible genes and activates transcription of these genes.

(+)-Ochromycinone

(STA-21)

Cat. No.: HY-121482

(+)-Ochromycinone is a natural antibiotic that potently inhibits STAT3. (+)-Ochromycinone is used in the researches of cancers and psoriasis.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(E/Z)-AG490

((E/Z)-Tyrphostin AG490; (E/Z)-Tyrphostin B42)

Cat. No.: HY-107459

(E/Z)-AG490 ((E/Z)-Tyrphostin AG490) is a racemic compound of (E)-AG490 and (Z)-AG490 isomers. (E)-AG490 (HY-12000) is a **tyrosine kinase** inhibitor that inhibits **EGFR**, **Stat-3** and **JAK2/3**.



Purity: ≥96.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(R)-Lisofylline

((R)-Lisophylline)

Cat. No.: HY-109854A

(R)-Lisofylline ((R)-Lisophylline) is a (R)-enantiomer of the metabolite of Pentoxifylline with anti-inflammatory properties.



Purity: ≥97.0%
Clinical Data: No Development Reported
Size: 5 mg

1-(4-Chloro-3-(trifluoromethyl)phenyl)-3-(4-(4-cyanophenoxy) phenyl)urea

Cat. No.: HY-136658

STAT3-IN-7 is a Sorafenib analogue and potently inhibits the phosphorylation of **STAT3**. STAT3-IN-7 induces cell apoptosis through SHP-1 dependent STAT3 inactivation. STAT3-IN-7 does not inhibit kinase activity and has anticancer effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

2-NP

Cat. No.: HY-W013523

2-NP is a selective enhancer of **STAT1** transcription. 2-NP can enhance the ability of IFN-γ to inhibit the proliferation of human breast cancer and fibrosarcoma cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

5,15-Diphenylporphyrin

(5,15-DPP)

Cat. No.: HY-W035137

5,15-Diphenylporphyrin (5,15-DPP) is a selective **STAT3-SH2** antagonist (IC_{50}s of 0.28 μM and 10 μM for STAT3 and STAT1, respectively).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AC-4-130

Cat. No.: HY-124500

AC-4-130 is a potent **STAT5 SH2** domain inhibitor. AC-4-130 directly binds to STAT5 and disrupts STAT5 activation, dimerization, nuclear translocation, and STAT5-dependent gene transcription.



Purity: 99.87%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

ACT001

Cat. No.: HY-128861A

ACT001 is an orally active **PAI-1** inhibitor by inhibiting the phosphorylation of **PI3K** and **AKT**. ACT001 inhibits the phosphorylation of STAT3 and PD-L1 expression by directly binding to **STAT3**.



Purity: 99.62%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

AG490

(Tyrphostin AG490; Tyrphostin B42)

Cat. No.: HY-12000

AG490 (Tyrphostin AG490) is a tyrosine kinase inhibitor that inhibits **EGFR**, **Stat-3** and **JAK2/3**.



Purity: 99.92%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

Alantolactone

((+)-Alantolactone; Alant camphor; Inula camphor)

Cat. No.: HY-N0038

Alantolactone is a selective **STAT3** inhibitor, with potent anticancer activity. Alantolactone induces apoptosis in cancer.



Purity: 99.94%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Angoline

Cat. No.: HY-N7674

Angoline is a potent and selective **IL6/STAT3 signaling pathway** inhibitor with an IC_{50} of 11.56 μM. Angoline inhibits STAT3 phosphorylation and its target gene expression, and inhibits cancer cell proliferation.



Purity: 99.67%
Clinical Data: No Development Reported
Size: 5 mg

Angoline hydrochloride

Cat. No.: HY-N7674A

Angoline hydrochloride is a potent and selective **IL6/STAT3 signaling pathway** inhibitor with an IC_{50} of 11.56 μM. Angoline hydrochloride inhibits STAT3 phosphorylation and its target gene expression, and inhibits cancer cell proliferation.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

APTSTAT3-9R

Cat. No.: HY-P2282

APTSTAT3-9R, a specific STAT3-binding peptide, inhibits STAT3 activation and downstream signaling by specifically blocking **STAT3** phosphorylation. APTSTAT3-9R exerts antiproliferative effects and antitumor activity.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Arnicolide D

Cat. No.: HY-N6843

Arnicolide D is a sesquiterpene lactone isolated from Centipeda minima. Arnicolide D modulates the cell cycle, activates the **caspase** signaling pathway and inhibits the **PI3K/AKT/mTOR** and **STAT3** signaling pathways.



Purity: 99.20%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Artesunate

Cat. No.: HY-N0193

Artesunate is an inhibitor of both **STAT-3** and **exported protein 1** (**EXP1**).



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg

Artesunate-d3

Cat. No.: HY-N0193S

Artesunate-d3 is the deuterium labeled Artesunate. Artesunate is an inhibitor of both **STAT-3** and **exported protein 1** (**EXP1**).



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mg

Artesunate-d4

Cat. No.: HY-N0193S1

Artesunate-d4 is deuterium labeled Artesunate. Artesunate is an inhibitor of both STAT-3 and exported protein 1 (EXP1).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AS1517499

Cat. No.: HY-100614

AS1517499 is a potent and brain-permeable **STAT6** phosphorylation inhibitor with an IC_{50} of 21 nM.



Purity: 99.17%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

AS1810722

Cat. No.: HY-134772

AS1810722 is an orally active and potent **STAT6** inhibitor with an IC_{50} of 1.9 nM. AS1810722 shows a good profile of **CYP3A4** inhibition. AS1810722, a derivative of fused bicyclic pyrimidine, has the potential for allergic diseases such as asthma and atopic diseases research.



Purity: 98.56%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

AS2863619

Cat. No.: HY-126675A

AS2863619 enables conversion of antigen-specific effector/memory T cells into Foxp3$^+$ regulatory T (T_{reg}) cells for the treatment of various immunological diseases.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AS2863619 free base

Cat. No.: HY-126675

AS2863619 free base enables conversion of antigen-specific effector/memory T cells into Foxp3$^+$ regulatory T (T_{reg}) cells for the treatment of various immunological diseases.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Ascochlorin

(Ilicicolin D)

Cat. No.: HY-101021

Ascochlorin (Ilicicolin D), an isoprenoid antibiotic, mediates its anti-tumor effects predominantly through the suppression of **STAT3** signaling cascade. Ascochlorin induces **apoptosis**. Anti-inflammatory activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 500 μg, 1 mg

Atractylenolide I

Cat. No.: HY-N0201

Atractylenolide I is a sesquiterpene derived from the rhizome of Atractylodes macrocephala, possesses diverse bioactivities, such as neuroprotective, anti-allergic, anti-inflammatory and anticancer properties.



Purity: 99.83%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Balsalazide

Cat. No.: HY-B0667

Balsalazide could suppress colitis-associated carcinogenesis through modulation of **IL-6/STAT3** pathway.



Purity: 99.20%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Balsalazide sodium hydrate

(Balsalazide disodium dihydrate)

Cat. No.: HY-B0667A

Balsalazide sodium hydrate could suppress colitis-associated carcinogenesis through modulation of **IL-6/STAT3** pathway.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Balsalazide-d4

Cat. No.: HY-B0667S1

Balsalazide-d4 is deuterium labeled Balsalazide. Balsalazide could suppress colitis-associated carcinogenesis through modulation of IL-6/STAT3 pathway.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BD750

Cat. No.: HY-131140

BD750, an effective immunosuppressant and a **JAK3/STAT5** inhibitor, inhibits IL-2-induced JAK3/STAT5-dependent T cell proliferation, with IC_{50} values of 1.5 μM and 1.1 μM in mouse and human T cells, respectively.



Purity: 99.79%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BP-1-102

Cat. No.: HY-100493

BP-1-102 is an orally available, small-molecule inhibitor of transcription factor **Stat3**, with an IC_{50} of 6.8 μM.



Purity: 98.98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Brevilin A

Cat. No.: HY-N2959

Brevilin A is a sesquiterpene lactone isolated from Centipeda minima with anti-tumor activity. Brevilin A is a selective inhibitor of **JAK-STAT** signal pathway by attenuating the JAKs activity and blocking STAT3 signaling (IC_{50} = 10.6 μM) in Cancer Cells.



Purity: 99.77%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

C188

(CPD188)

Cat. No.: HY-112338

C188 is a **STAT3** inhibitor that inhibits IL-6-stimulated STAT3 phosphorylation and nuclear translocation in HepG2 cells by targeting STAT3 SH2 domain peptide-binding pocket.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

C188-9

(TTI-101)

Cat. No.: HY-112288

C188-9 (TTI-101) is a **STAT3** inhibitor, with a K_d of 4.7 nM. C188-9 inhibits G-CSF-induced STAT3 activation and STAT3-dependent gene expression. C188-9 induces **apoptosis** in AML cell lines and primary samples and inhibits colony formation by primary AML blasts.



Purity: 99.90%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Casticin

(Vitexicarpin)

Cat. No.: HY-N0516

Casticin is a methyoxylated flavonol isolated from Viticis Fructus, with antimitotic and anti-inflammatory effect. Casticin inhibits the activation of **STAT3**.



Purity: 99.67%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Cenisertib

(AS-703569; R-763)

Cat. No.: HY-13072

Cenisertib (AS-703569) is an ATP-competitive multi-kinase inhibitor that blocks the activity of **Aurora-kinase-A/B, ABL1, AKT, STAT5 and FLT3**.



Purity: 99.64%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Cirsilineol

Cat. No.: HY-119347

Cirsilineol, a natural flavone compound, selectively inhibits IFN-γ/STAT1/T-bet signaling in intestinal $CD4^+$ T cells. Cirsilineol has potent immunosuppressive and anti-tumor properties.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CMD178

Cat. No.: HY-P1453

CMD178 is a lead peptide that consistently reduced the expression of Foxp3 and STAT5 induced by IL-2/s IL-2Rα signaling. CMD178 also is an inhibitor of STAT5 and inhibit T_{reg} cell development.

RFKF[Y(OBn)]

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CMD178 TFA

Cat. No.: HY-P1453A

CMD178 (TFA) is a lead peptide that consistently reduces the expression of Foxp3 and STAT5 induced by IL-2/s IL-2Rα signaling. CMD178 (TFA) also is an inhibitor of **STAT5** and inhibits T_{reg}cells development.

RFKF[Y(OBn)]



Purity: 98.72%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

Colivelin

Cat. No.: HY-P1061

Colivelin is a brain penetrant **neuroprotective peptide** and a potent activator of **STAT3**, suppresses neuronal death by activating STAT3 in vitro.

SALLRSIPAPAGASRLLLLTGEIDLP

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Colivelin TFA

Cat. No.: HY-P1061A

Colivelin TFA is a brain penetrant **neuroprotective peptide** and a potent activator of **STAT3**, suppresses neuronal death by activating STAT3 in vitro.

SALLRSIPAPAGASRLLLLTGEIDLP (TFA salt)

Purity: 99.22%
Clinical Data: No Development Reported
Size: 500 μg, 1 mg

Corylifol A

(Corylifol-A; Corylinin)

Cat. No.: HY-N0897

Corylifol A inhibits IL-6-induced **STAT3** activation and phosphorylation, with an IC_{50} of 0.81 μM.



Purity: 99.75%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Cryptotanshinone

(Cryptotanshinon; Tanshinone c)

Cat. No.: HY-N0174

Cryptotanshinone is a natural compound extracted from the root of Salvia miltiorrhiza Bunge that shows antitumor activities. Cryptotanshinone inhibits **STAT3** with an IC_{50} of 4.6 μM.



Purity: 98.46%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

Cucurbitacin I

(Elatericin B; JSI-124; NSC-521777)

Cat. No.: HY-N1405

Cucurbitacin I is a natural selective inhibitor of **JAK2/STAT3**, with potent anti-cancer activity.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

Curculigoside

Cat. No.: HY-N0705

Curculigoside is the main saponin in C. orchioide, exerts significant antioxidant, anti-osteoporosis, antidepressant and neuroprotection effects. Curculigoside possesses significant anti-arthritic effects in vivo and in vitro via regulation of the **JAK/STAT/NF-κB** signaling pathway.



Purity: 99.73%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

Danvatirsen

(AZD 9150)

Cat. No.: HY-145729

Danvatirsen is an antisense oligonucleotide targeting **STAT3** with potential antitumor activity. Danvatirsen binds to STAT3 mRNA, thereby inhibiting translation of the transcript. Suppression of STAT3 expression induces tumor cell apoptosis and decreases tumor cell growth.

Danvatirsen

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Debio 0617B

Cat. No.: HY-108417

Debio 0617B, a multi-kinase inhibitor, reduces maintenance and self-renewal of primary human AML $CD34^+$ stem/progenitor cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Delphinidin chloride

Cat. No.: HY-N2409

Delphinidin chloride, an anthocyanidin, is isolated from berries and red wine. Delphinidin chloride shows endothelium-dependent vasorelaxation. Delphinidin chloride also can modulate JAK/STAT3 and MAPKinase signaling to induce apoptosis in HCT116 cells.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Dihydroisotanshinone I

Cat. No.: HY-B1919

Dihydroisotanshinone I, a bioactive compound present in danshen, can inhibit the migration of both androgen-dependent and androgen-independent prostate cancer cells. Dihydroisotanshinone I also induces **apoptosis** and **ferroptosis** in these lung cancer cells.



Purity: 99.52%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Diosgenin

Cat. No.: HY-N0177

Diosgenin, a steroidal saponin, can inhibit **STAT3** signaling pathway. Diosgenin is an exogenous activator of **Pdia3/ERp57**.



Purity: 99.20%
Clinical Data: No Development Reported
Size: 100 mg

ENMD-1198

(IRC-110160)

Cat. No.: HY-16196

ENMD-1198 (IRC-110160), an orally active **microtubule destabilizing** agent, is a 2-methoxyestradiol analogue with antiproliferative and antiangiogenic activity.



Purity: 98.87%
Clinical Data: No Development Reported
Size: 1 mg

Eupalinolide K

Cat. No.: HY-N2240

Eupalinolide K, a sesquiterpene lactones compound from Eupatorium lindleyanum, is a **STAT3** inhibitor. Eupalinolide K is a Michael reaction acceptor (MRA) .



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FLLL32

Cat. No.: HY-100544

FLLL32, a synthetic analog of curcumina, is a **JAK2/STAT3** dual inhibitor with anti-tumor activity. FLLL32 can inhibit the induction of STAT3 phosphorylation by IFNα and IL-6 in breast cancer cells.



Purity: 99.78%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Fludarabine

(F-ara-A; NSC 118218)

Cat. No.: HY-B0069

Fludarabine (NSC 118218) is a **DNA synthesis** inhibitor and a fluorinated purine analogue with antineoplastic activity in lymphoproliferative malignancies.



Purity: 99.85%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Fraxinellone

Cat. No.: HY-N0242

Fraxinellone is isolated from the root bark of the Rutaceae plant, Dictamnus dasycarpus. Fraxinellone is a **PD-L1** inhibitor and inhibits **HIF-1α** protein synthesis without affecting HIF-1α protein degradation.



Purity: 99.99%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 20 mg

Galiellalactone

Cat. No.: HY-125170

Galiellalactone is a is a small non-toxic and non-mutagenic fungal metabolite, a selective inhibitor of **STAT3 signaling**, with an IC_{50} of 250-500 nM. Galiellalactone can be used to research castration-resistant prostate cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Garcinone C

Cat. No.: HY-N6954

Garcinone C, a xanthone derivative, is a natural compound extracted from Garcinia oblongifolia Champ that is used as an anti-inflammatory, astringency and granulation-promoting medicine, and has potential cytotoxic effects on certain cancers.



Purity: 99.66%
Clinical Data: No Development Reported
Size: 1 mg

Garcinone D

Cat. No.: HY-N6953

Garcinone D, a natural xanthone from mangosteen, promotes the proliferation of C17.2 neural stem cell.



Purity: 98.19%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

Golotimod

(SCV 07; Gamma-D-glutamyl-L-tryptophan)

Cat. No.: HY-14743

Golotimod (SCV-07), an immunomodulating peptide with antimicrobial activity, significantly increases the efficacy of antituberculosis therapy, stimulates thymic and splenic cell proliferation, and improves macrophage function.



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

Golotimod hydrochloride (SCV 07 hydrochloride; Gamma-D-glutamyl-L-tryptophan hydrochloride)

Cat. No.: HY-14743B

Golotimod hydrochloride (SCV 07 hydrochloride), an immunomodulating peptide with antimicrobial activity, significantly increases the efficacy of antituberculosis therapy, stimulates thymic and splenic cell proliferation, and improves macrophage function.



Purity: 98.90%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Golotimod TFA

(SCV 07 TFA; Gamma-D-glutamyl-L-tryptophan TFA)

Cat. No.: HY-14743A

Golotimod TFA (SCV 07 TFA), an immunomodulating peptide with antimicrobial activity, significantly increases the efficacy of antituberculosis therapy, stimulates thymic and splenic cell proliferation, and improves macrophage function.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HJC0152 hydrochloride

Cat. No.: HY-100602

HJC0152 hydrochloride is a **signal transducers and activators of transcription 3** (**STAT3**) inhibitor.



Purity: 98.95%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

HJC0416 hydrochloride

Cat. No.: HY-12352A

HJC0416 hydrochloride is a potent and orally active **STAT3** inhibitor with an enhanced anticancer profile than Stattic (HY-13818). HJC0416 hydrochloride is a promising anti-cancer agent for breast cancer study.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HO-3867

Cat. No.: HY-100453

HO-3867 is a selective and potent **STAT3** inhibitor and shows good antitumor activity.



Purity: 98.26%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Homoharringtonine

(Omacetaxine mepesuccinate; HHT)

Cat. No.: HY-14944

Homoharringtonine (Omacetaxine mepesuccinate;HHT) is a cytotoxic alkaloid with antitumor properties which acts by inhibiting **translation elongation**.



Purity: 99.96%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

inS3-54A18

Cat. No.: HY-103128

inS3-54A18 is a potent **STAT3** inhibitor, with anti-cancer properties.



Purity: 99.83%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

L002

Cat. No.: HY-100671

L002 is a potent, cell permeable, reversible and specific **acetyltransferase p300 (KAT3B)** inhibitor with an IC_{50} of 1.98 μM.



Purity: 98.80%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MM-206

Cat. No.: HY-121725

MM-206, a **STAT3** activity inhibitor, potently inhibits the STAT3 SH2 domain-phosphopeptide interaction with IC_{50} of 1.2 μM. MM-206 demonstrates dose-dependent induction of apoptosis in acute myeloid leukemia (AML) cell lines.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mogrol

Cat. No.: HY-N2312

Mogrol is a biometabolite of mogrosides, and acts via inhibition of the **ERK1/2** and **STAT3** pathways, or reducing **CREB** activation and activating **AMPK** signaling.



Purity: 99.25%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg

Morusin

(Mulberrochromene)

Cat. No.: HY-N0622

Morusin is a prenylated flavonoid isolated from M. australis with various biological activities, such as antitumor, antioxidant, and anti-bacteria property. Morusin could inhibit **NF-κB** and **STAT3** activity.



Purity: 99.83%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg

Napabucasin

(BBI608)

Cat. No.: HY-13919

Napabucasin (BBI608) is a **STAT3** inhibitor which blocks stem cell activity in cancer cells.



Purity: 99.27%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Niclosamide

(BAY2353)

Cat. No.: HY-B0497

Niclosamide (BAY2353) is an orally bioavailable chlorinated salicylanilide, with anthelmintic and potential antineoplastic activity. Niclosamide (BAY2353) inhibits **STAT3** with IC_{50} of 0.25 μM in HeLa cells and inhibits DNA replication in a cell-free assay.



Purity: 98.68%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 5 g, 10 g

Niclosamide monohydrate

(BAY2353 monohydrate)

Cat. No.: HY-B0497B

Niclosamide monohydrate is an inhibitor of **STAT3** with IC_{50} of 0.25 μM in HeLa cells and inhibits DNA replication in a cell-free assay.



Purity: >98%
Clinical Data: Launched
Size: 500 mg

Niclosamide olamine

(BAY2353 olamine)

Cat. No.: HY-B0497C

Niclosamide olamine (BAY2353 olamine) is an anthelmintic that disrupts mitochondrial metabolism in parasitic worms and animal models.



Purity: >98%
Clinical Data: Phase 4
Size: 1 mg, 5 mg

Nifuroxazide

Cat. No.: HY-B1436

Nifuroxazide is an effective inhibitor of **STAT3**, also exerts potent anti-tumor and anti-metastasis activity.



Purity: 98.55%
Clinical Data: Launched
Size: 10 mM × 1 mL, 200 mg, 500 mg

Nifuroxazide-d4

Cat. No.: HY-B1436S

Nifuroxazide-d4 is the deuterium labeled Nifuroxazide. Nifuroxazide is an effective inhibitor of **STAT3**, also exerts potent anti-tumor and anti-metastasis activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

Nitidine chloride

Cat. No.: HY-N0498

Nitidine chloride, a potential **anti-malarial** lead compound derived from Zanthoxylum nitidum (Roxb) DC, exerts potent anticancer activity through diverse pathways, including inducing **apoptosis**, inhibiting **STAT3** signaling cascade, **DNA topoisomerase 1 and 2A**, **ERK** and...



Purity: 99.61%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

NSC 74859

(S3I-201)

Cat. No.: HY-15146

NSC 74859 (S3I-201) is a selective **Stat3** inhibitor with an IC_{50} of 86 μM.



Purity: 98.64%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

NT219

Cat. No.: HY-145935

NT219 is a potent and dual inhibitor of insulin receptor substrates 1/2 (**IRS1/2**) and **STAT3**. IRS1/2 and STAT3 are major signaling junctions regulated by various oncogenes. NT219 affects IRS1/2 degradation and inhibits STAT3 phosphorylation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ochromycinone

((Rac)-STA-21)

Cat. No.: HY-18061

Ochromycinone ((Rac)-STA-21) is a natural antibiotic and a **STAT3** inhibitor. Ochromycinone can inhibits **STAT3** DNA binding activity, **STAT3** dimerization. Ochromycinone has anticancer and antimicrobial activity.



Purity: 99.11%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Picroside I

(6'-Cinnamoylcatalpol)

Cat. No.: HY-N0407

Picroside I is the major ingredient of Picrorhiza kurroa. Picrorhiza kurroa is a high value medicinal herb due to rich source of hepatoprotective metabolites, Picroside-I and Picroside-II. Picroside I is a promising agent for the management of asthma.



Purity: 99.55%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 20 mg

Pimozide

(R6238)

Cat. No.: HY-12987

Pimozide is a **dopamine receptor** antagonist, with K_is of 1.4 nM, 2.5 nM and 588 nM for dopamine D2, D3 and D1 receptors, respectively, and also has affinity at **α1-adrenoceptor**, with a K_i of 39 nM; Pimozide also inhibits **STAT3** and **STAT5**.



Purity: 99.88%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg

Pimozide-d4

(R6238-d4)

Cat. No.: HY-12987S

Pimozide D4 (R6238 D4) is a deuterium labeled Pimozide.



Purity: >98%
Clinical Data: Phase 4
Size: 1 mg, 5 mg

Pimozide-d5 N-Oxide

Cat. No.: HY-12987S1

Pimozide-d5 N-Oxide is the deuterium labeled Pimozide.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

Protosappanin A

(PTA)

Cat. No.: HY-113573

Protosappanin A (PTA), an immunosuppressive ingredient and major biphenyl compound isolated from Caesalpinia sappan L, suppresses **JAK2/STAT3**-dependent inflammation pathway through down-regulating the phosphorylation of JAK2 and STAT3.



Purity: 99.98%
Clinical Data:
Size: 1 mg, 5 mg, 10 mg

Reticuline

Cat. No.: HY-N1356

Reticuline shows anti-inflammatory effects through **JAK2/STAT3** and **NF-κB** signaling pathways. Reticuline inhibits mRNA expressions of TNF-α, and IL-6 and reduces the phosphorylation levels of JAK2 and STAT3. Reticuline exhibits cardiovascular effects.



Purity: 98.11%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Reticuline-d3

Cat. No.: HY-N1356S

Reticuline-d3 is the deuterium labeled Reticuline. Reticuline shows anti-inflammatory effects through **JAK2/STAT3** and **NF-κB** signaling pathways. Reticuline inhibits mRNA expressions of TNF-α, and IL-6 and reduces the phosphorylation levels of JAK2 and STAT3.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RO8191

(CDM-3008; RO4948191)

Cat. No.: HY-W063968

RO8191 (CDM-3008), an imidazonaphthyridine compound, is an orally active and potent **interferon (IFN) receptor** agonist. RO8191 directly binds to IFNα/β receptor 2 (IFNAR2) and activates IFN-stimulated genes (ISGs) expression and **JAK/STAT** phosphorylation.



Purity: 98.53%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

RSVA405

Cat. No.: HY-103238

RSVA405 is a potent, orally active activator of **AMPK**, with an EC_{50} of 1 μM. RSVA405 facilitates CaMKKβ-dependent activation of AMPK, inhibits **mTOR**, and promotes **autophagy** to increase Aβ degradation.



Purity: 99.56%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Saikosaponin D

Cat. No.: HY-N0250

Saikosaponin D is a triterpene saponin isolated from Bupleurum, with anti-inflammatory, anti-bacterial, anti-tumor, and anti-allergic activities; Saikosaponin D inhibits **selectin**, **STAT3** and **NF-kB** and activates **estrogen receptor-β**.



Purity: 98.76%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SC-43

Cat. No.: HY-136657

SC-43, a Sorafenib derivative, is a potent and orally active **SHP-1 (PTPN6)** agonist. SC-43 inhibits the phosphorylation of **STAT3** and induces cell **apoptosis**. SC-43 has anti-fibrotic and anticancer effects.



Purity: 98.61%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

SC99

Cat. No.: HY-124858

SC99 is an orally active, selective **STAT3** inhibitor targeting JAK2-STAT3 pathway. SC99 docks into the ATP-binding pocket of JAK2. SC99 inhibits phosphorylation of JAK2 and STAT3 with no effects on the other kinases associated with STAT3 signaling.



Purity: 99.07%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Scutellarin

Cat. No.: HY-N0751

Scutellarin, an active flavone isolated from Scutellaria baicalensis, can down-regulates the **STAT3/Girdin/Akt** signaling in HCC cells, and inhibits RANKL-mediated **MAPK and NF-κB** signaling pathway in osteoclasts.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg

SD-1008

Cat. No.: HY-107595

SD-1008 is a potent **JAK** inhibitor. SD-1008 inhibits tyrosyl phosphorylation of STAT3, JAK2 and Src. SD-1008 also reduces STAT3-dependent luciferase activity. SD-1008 enhances **apoptosis** induced by Paclitaxel in ovarian cancer cells via directly blocking the JAK-STAT3 signaling pathway.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SD-1029

Cat. No.: HY-112391

SD-1029 is a **JAK2/STAT3** inhibitor. SD-1029 inhibits STAT3 nuclear translocation. SD-1029 is an inhibitor of STAT3 activation due to inhibition of JAK2 phosphorylation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SD-36

Cat. No.: HY-129602

SD-36 is a potent and efficacious **STAT3** PROTAC degrader (K_d=~50 nM), and demonstrates high selectivity over other STAT members. SD-36 also effectively degrades mutated STAT3 proteins in cells and suppresses the transcriptional activity of STAT3 (IC_{50}=10 nM).



Purity: 99.46%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

SH-4-54

Cat. No.: HY-16975

SH-4-54 is a **STAT** inhibitor that binds to STAT3 and STAT5 with K_Ds of 300, 464 nM, respectively.



Purity: 99.59%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SH5-07

Cat. No.: HY-100494

SH5-07 is a hydroxamic acid based **Stat3** inhibitor with an IC_{50} of 3.9 μM in in vitro assay.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

SI-109

Cat. No.: HY-129603

SI-109 is a potent **STAT3 SH2 domain** inhibitor (K_i=9 nM) with antitumor activity. SI-109 effectively inhibits the transcriptional activity of STAT3 (IC_{50}=3 μM). SI-109 and an analog of CRBN ligand lenalidomide have been used to design PROTAC STAT3 degrader **SD-36**.



Purity: 99.48%
Clinical Data: No Development Reported
Size: 5 mg

Stafia-1

Cat. No.: HY-136546

Stafia-1 is a potent **STAT5a** inhibitor (K_i=10.9 μM, IC_{50}=22.2 μM). Stafia-1 displays high selectivity over STAT5b and other STAT family members.



Purity: 99.53%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Stafia-1-dipivaloyloxymethyl ester

Cat. No.: HY-136568

Stafia-1-dipivaloyloxymethyl ester (compound 27, 0-200 μM) decreases pSTAT5a expression significantly, and has no obvious inhibition on pSTAT5b.



Purity: 98.31%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Stafib-1

Cat. No.: HY-112647

Stafib-1 is the first selective inhibitor of the **STAT5b SH2** domain, with a K_i of 44 nM and an IC_{50} of 154 nM.



Purity: 95.04%
Clinical Data: No Development Reported
Size: 5 mg

Stafib-2

Cat. No.: HY-112648

Stafib-2 is a potent and selctive inhibitor of the **transcription factor STAT5b**, with an IC_{50} of 82 nM and 1.7 μM for **STAT5b** and **STAT5a**, respectively. Stafib-2 exhibits poor cell permeability.



Purity: 95.64%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

STAT3-IN-1

Cat. No.: HY-100753

STAT3-IN-1 (compound 7d) is an excellent, selective and orally active **STAT3** inhibitor, with IC_{50} values of 1.82 μM and 2.14 μM in HT29 and MDA-MB 231 cells, respectively. STAT3-IN-1 (compound 7d) induces tumor apoptosis.



Purity: 96.54%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

STAT3-IN-10

Cat. No.: HY-146728

STAT3-IN-10 (A11) is a **STAT3** inhibitor with an IC_{50} value of 5.18 μM. STAT3-IN-10 directly binds to STAT3 SH2 domain, inhibits tumor cell growth and induces **apoptosis** in cancer cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

STAT3-IN-3

Cat. No.: HY-128588

STAT3-IN-3 is a potent and selective inhibitor of **signal transducer and activator of transcription 3 (STAT3)**, with anti-proliferative activity. STAT3-IN-3 induces **apoptosis** in breast cancer cells.



Purity: 98.23%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

STAT3-IN-7

Cat. No.: HY-144870

STAT3-IN-7, an aryl sulfonamido azetidine compound, is an orally active **STAT3** inhibitor. STAT3-IN-7 has anticancer activities (WO2021016333A1, H182).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

STAT3-IN-8

Cat. No.: HY-144871

STAT3-IN-8 (compound H172) is a potent **STAT3** inhibitor. STAT3-IN-8 has the potential for cancer research.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

STAT5-IN-1

Cat. No.: HY-101853

STAT5-IN-1 is a **STAT5** inhibitor with an IC_{50} of 47 μM for STAT5β isoform.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

STAT5-IN-2

Cat. No.: HY-102048

STAT5-IN-2 is a **STAT5** inhibitor, extracted from reference 1, example 17f. STAT5-IN-2 has potent antileukemic effect.



Purity: 99.01%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Stattic

Cat. No.: HY-13818

Stattic is a potent **STAT3** inhibitor and inhibits STAT3 phosphorylation (at Y705 and S727). Stattic inhibits the binding of a high affinity phosphopeptide for the SH2 domain of STAT3. Stattic ameliorates the renal dysfunction in Alport syndrome (AS) mice.



Purity: ≥97.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg

Tetramethylcurcumin

(FLLL31)

Cat. No.: HY-N2521

Tetramethylcurcumin (FLLL31), derived from curcumin, specifically suppresses the phosphorylation of **STAT3** by binding selectively to Janus kinase 2 and the STAT3 Src homology-2 domain. Tetramethylcurcumin exhibits anti-inflammatory and anti-cancer effects.



Purity: 99.91%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

TPCA-1

Cat. No.: HY-10074

TPCA-1 is a potent and selective inhibitor of **IKK-2** with IC_{50} of 17.9 nM. TPCA-1 is an effective inhibitor of **STAT3** phosphorylation, DNA binding, and transactivation.



Purity: 99.58%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Triacetylresveratrol

Cat. No.: HY-N1410

Triacetylresveratrol, an acetylated analog of Resveratrol. Triacetylresveratrol decreases the phosphorylation of **STAT3** and **NF-κB** in a dose- and time- dependent manner in PANC-1 and BxPC-3 cells. Anticancer effects.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg

UC-514321

Cat. No.: HY-120395

UC-514321, a structural analog of NSC370284 with higher activity, directly targets **STAT3/5** and represses **TET1** expression, but not TET2 or TET3. UC-514321 has the potential to treat acute myeloid leukemia (AML) both in vitro and in vivo, with low toxicity.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

WP1066

Cat. No.: HY-15312

WP1066 is an inhibitor of **JAK2** and **STAT3**, and also shows effect on STAT5 and ERK1/2, without affecting JAK1 and JAK3.



Purity: 99.90%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 10 mg, 50 mg

YM-341619

(AS1617612)

Cat. No.: HY-134771

YM-341619 (AS1617612) is a potent and orally active **STAT6** inhibitor with an IC_{50} of 0.70 nM. YM-341619 inhibits Th2 differentiation in mouse spleen T cells induced by IL-4 (IC_{50}=0.28 nM) without affecting Th1 cell differentiation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

α7 nAchR-JAK2-STAT3 agonist 1

Cat. No.: HY-146066

α7 nAchR-JAK2-STAT3 agonist 1 is a potent **α7 nAchR-JAK2-STAT3** agonist, with an IC_{50} value of 0.32 μM for **nitric oxide (NO)**. α7 nAchR-JAK2-STAT3 agonist 1 effectively suppresses the expression of iNOS, IL-1β, and IL-6 in murine RAW264.7 macrophages.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg